OIS@ASRS

DARC – a New Retinal Imaging Biomarker

Detection of Apoptosing Retinal Cells (DARC) – a New Retinal Imaging Biomarker

By Mario Admin | August 21, 2017

M. Francesca Cordeiro, MD, PhD, professor, UCL and Imperial College London, Western Eye Hospital London, introduces a promising new technology that could enable much earlier…

Read More
Can Drusolv Therapeutics Use Statins to Treat Intermediate AMD?

Can Drusolv Use Statins to Treat Intermediate AMD?

By Mario Admin | August 21, 2017

John Edwards, CEO of Drusolv Therapeutics, lays out the company’s plan to use statins as a treatment for intermediate AMD. The firm is based off…

Read More
ProFarma Seeks $6 Million Series A to Advance Neuroprotective Pipeline

ProFarma Seeks $6 Million Series A to Advance Neuroprotective Pipeline

By Mario Admin | August 21, 2017

Remis Bistras, CEO of ProFarma, lays out the company’s plan to improve the delivery and effective life of drugs that strengthen neuroprotectiveness in retina ganglion…

Read More
Translatum Medicus Moves Forward with FDA

Translatum Moves Forward, Plans to Engage FDA

By Mario Admin | August 21, 2017

Shelley Boyd, MD, president and chief scientific officer, says Translatum Medicus Inc. has raised its first angel round based upon the potential of the company’s…

Read More
ONL Therapeutics updates OIS on the development program of Fas inhibitors

Flush with $5 m, ONL Pushes Forward to Test ONL 1204 as Retinal Detachment Treatment

By Mario Admin | August 21, 2017

John Freshley, president and CEO of ONL Therapeutics, updates OIS on the development program of Fas inhibitors. The company’s lead product is ONL 1204, which…

Read More
Stealth BioTherapeutics' New Approach to Treating Eye Diseases

Stealth BioTherapeutics Pushing Innovative New Approach to Treating Eye Diseases

By Mario Admin | August 21, 2017

Reenie McCarthy, CEO of Stealth BioTherapeutics, introduces the company’s early-stage clinical program testing mitochondrial medicine as treatment for ophthalmic conditions. McCarthy details three ongoing clinical…

Read More
Aerpio Pharmaceuticals Kicking Off Phase IIb Studies

Aerpio Kicking Off Phase IIb Studies for Promising First-in-Class Pipeline

By Mario Admin | August 21, 2017

Joseph Gardner, president and CEO, introduces the company’s first-in-class pipeline targeting the Tie2/VE-PTP pathway. Gardner delivers an extensive overview of Aerpio’s AKB-9778, a novel small…

Read More
Ohr Pharmaceutical to Release Top-line Phase III Trials Early 2018

Ohr Expects to Release Top-line Phase III Trials Next Year

By Mario Admin | August 21, 2017

Jason Slakter, MD, CEO, lays out a pivotal year for Ohr Pharmaceutical’s squalamine lactate, an intracellular treatment for wet AMD. Dr. Slakter reviews early results…

Read More
What Were the Highlights of OIS@ASRS? Let’s Ask the Co-Chairs Drs. Cunningham, Humayun, and Pollack

What Were the Highlights of OIS@ASRS? Let’s Ask the Co-Chairs Drs. Cunningham, Humayun, and Pollack

By Mario Admin | August 16, 2017

OIS@ASRS co-chairs Emmett Cunningham Jr., MD, Mark S. Humayun, MD, PhD, and John Pollack, MD, took a few minutes to share their thoughts on the…

Read More
What Eight Qualities Do Funders Look for in Founders Before Investing in a Start-up?

What Eight Qualities Do Funders Look for in Founders Before Investing in a Start-up?

By Mario Admin | August 16, 2017

Candor, passion, realism, talent, flexibility, self awareness, humility, and focus are all qualities seed-stage benefactors look for in a start-up founder, fund managers said at…

Read More
pSivida Shares Promising Clinical Trial Data

Watch Promising Clinical Trial Data from pSivida

By Mario Admin | August 15, 2017

Deb Jorn, EVP, corporate development, shares promising results from three clinical trials of the company’s Durasert delivery product. She also shares pSivida’s plans to file…

Read More
Alimera Sciences Reveals Details of Promising New Illuvien Trial

Myers Reveals Details of Promising New Illuvien Trial

By Mario Admin | August 15, 2017

Dan Myers, CEO, discusses the promise and challenges facing the Alimera’s development of Illuvien for the treatment of DME. He shares results from the firm’s…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.